# Pharming Group N.V. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Pharming Group N.V.). ## Overview Pharming Group N.V. is a Dutch biopharmaceutical company focused on medicines for rare, debilitating, and life-threatening diseases. Its business combines the development and commercialization of small-molecule and biologic therapies through operations in Europe and the United States. ## Products & services • RUCONEST® for hereditary angioedema • Joenja® (leniolisib) for APDS • Development of rare-disease biologics • Development of small-molecule medicines - **Commercial rare-disease medicines** (90%) — Approved therapies sold to patients with rare immune and inflammatory diseases. - **Biologic therapies** (55%) — Protein-based medicines developed and commercialized for specialty indications. - **Small-molecule therapies** (45%) — Oral or chemically synthesized medicines used in rare-disease treatment. - **Pipeline and development programs** (0%) — Research and clinical programs intended to expand the rare-disease portfolio. - RUCONEST® for hereditary angioedema - Joenja® (leniolisib) for APDS - Development of rare-disease biologics - Development of small-molecule medicines ## Customers Pharming sells into the rare-disease treatment ecosystem, where demand is driven by specialist physicians, hospitals, and treatment centers managing complex genetic or immunological disorders. Patients ultimately receive the therapies through healthcare providers and reimbursing payers, so access and diagnosis are important commercial drivers. The company also depends on healthcare systems and pharmacies that support specialty-drug distribution. - **Specialist physicians and clinics** (primary) — Prescribe RUCONEST® and Joenja® for rare-disease patients based on diagnosis and clinical need. - **Hospitals and treatment centers** (primary) — Administer or coordinate specialty therapies for severe, medically complex cases. - **Payers and national health systems** (primary) — Approve reimbursement and influence access to high-cost orphan medicines. - **Specialty pharmacies** (secondary) — Distribute the medicines to patients and support fulfillment of prescriptions. - Specialist physicians treating rare immunology patients - Hospitals and specialty treatment centers - Payers and reimbursement systems covering specialty drugs - Specialty pharmacies and distribution channels - Patients diagnosed with hereditary angioedema or APDS ## Geography Pharming is headquartered in Leiden, the Netherlands, and operates across the United States and Europe. The company’s commercial footprint is international, with the U.S. an important market for approved rare-disease medicines and Europe supporting both commercial and corporate operations. Because its products are specialty therapies, access, reimbursement, and regulatory approvals vary by country and can shape market opportunity. - Headquartered in Leiden, the Netherlands - U.S. operations support commercial execution and investor access - European operations support sales, development, and corporate functions - International rare-disease markets depend on local reimbursement - Country-level access can affect adoption of specialty medicines ## Strategy Pharming’s strategy centers on building and commercializing a portfolio of rare-disease medicines, with a focus on expanding use of RUCONEST® and Joenja® and broadening its therapeutic reach. The business also relies on maintaining regulatory, clinical, and commercial execution in multiple markets, where patient identification and reimbursement are key to growth. Portfolio expansion through biologics and small molecules supports longer-term diversification beyond a single product. - **Grow the commercial rare-disease portfolio** (short-term) — Commercial medicines are the core revenue engine and support scale in specialty markets. - **Broaden the pipeline across biologics and small molecules** (medium-term) — Diversification reduces reliance on any one therapy and extends the company’s addressable market. - **Strengthen global market access** (medium-term) — Rare-disease products depend on reimbursement, diagnosis, and specialist adoption in each country. - Grow commercial adoption of RUCONEST® - Expand access and use of Joenja® (leniolisib) - Advance a diversified rare-disease portfolio - Maintain regulatory and clinical execution - Support global commercialization in U.S. and Europe ## Risks Pharming’s business is exposed to clinical, regulatory, and commercial risks typical of rare-disease drug developers, including trial outcomes, market access, and competitive therapies. Because revenues depend on a small number of specialty products, adoption, reimbursement, and physician diagnosis rates can materially affect performance. The company also faces execution risk in commercialization and the ongoing need to support its development pipeline. - **Clinical development risk** [high] — Pipeline programs depend on successful trial design, enrollment, and data outcomes. - **Market access and reimbursement risk** [high] — Specialty medicines require payer coverage and country-level reimbursement decisions. - **Product concentration risk** [high] — Revenue depends on a limited number of therapies in narrow patient populations. - **Regulatory risk** [medium] — Approvals, label changes, and post-marketing obligations can affect sales and development timelines. - Dependence on a small rare-disease product portfolio - Regulatory and clinical trial risk in development programs - Reimbursement and market-access risk for specialty drugs - Competition from alternative therapies and new entrants - Commercial execution risk in niche physician markets ## Accounting For a biopharmaceutical company, revenue recognition and commercialization judgments are important because specialty-drug sales can involve complex distributor, reimbursement, and return considerations. Clinical development costs and intangible asset assessments are also important because the value of the pipeline depends on technical and regulatory success. Interim reporting and going-concern assessments show that judgment is needed around forecasts, funding, and the timing of future cash generation. - **Revenue recognition** — Affects reported revenue and margins - **Returns and rebates** — Affects net revenue and receivables - **Intangible assets and development costs** — Affects amortization and impairment risk - **Going concern assessment** — Affects disclosure and liquidity analysis - Revenue recognition for specialty medicine sales - Estimates for returns, rebates, and allowances - Capitalization and impairment of intangible assets - Clinical development expense recognition - Going-concern and forecast assumptions --- *Last updated: 2026-09-28T12:13:41.117218+00:00*